CL2023001836A1 - Tratamiento de glomerulopatía c3 usando un inhibidor de c5a - Google Patents
Tratamiento de glomerulopatía c3 usando un inhibidor de c5aInfo
- Publication number
- CL2023001836A1 CL2023001836A1 CL2023001836A CL2023001836A CL2023001836A1 CL 2023001836 A1 CL2023001836 A1 CL 2023001836A1 CL 2023001836 A CL2023001836 A CL 2023001836A CL 2023001836 A CL2023001836 A CL 2023001836A CL 2023001836 A1 CL2023001836 A1 CL 2023001836A1
- Authority
- CL
- Chile
- Prior art keywords
- glomerulopathy
- inhibitor
- treatment
- susceptible
- administering
- Prior art date
Links
- 208000029574 C3 glomerulopathy Diseases 0.000 title abstract 2
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 title abstract 2
- 229940110394 C5a inhibitor Drugs 0.000 title 1
- 108010073240 complement C5a-inhibitors Proteins 0.000 title 1
- 229940126681 complement 5a receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128397P | 2020-12-21 | 2020-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001836A1 true CL2023001836A1 (es) | 2023-11-17 |
Family
ID=82159849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001836A CL2023001836A1 (es) | 2020-12-21 | 2023-06-20 | Tratamiento de glomerulopatía c3 usando un inhibidor de c5a |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220257580A1 (es) |
| EP (1) | EP4262800A1 (es) |
| JP (1) | JP2024500752A (es) |
| KR (1) | KR20230124981A (es) |
| CN (1) | CN116635075A (es) |
| AU (1) | AU2021410668A1 (es) |
| CA (1) | CA3205474A1 (es) |
| CL (1) | CL2023001836A1 (es) |
| IL (1) | IL303776A (es) |
| MX (1) | MX2023007420A (es) |
| TW (1) | TW202241423A (es) |
| WO (1) | WO2022140258A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102593431B1 (ko) | 2014-09-29 | 2023-10-23 | 케모센트릭스, 인크. | Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체 |
| MA43872A (fr) | 2016-01-14 | 2021-05-19 | Chemocentryx Inc | Procédé de traitement d'une glomérulopathie à c3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105392803B (zh) * | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
| MA43872A (fr) * | 2016-01-14 | 2021-05-19 | Chemocentryx Inc | Procédé de traitement d'une glomérulopathie à c3 |
| CA3019137A1 (en) * | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | Soluble c5ar antagonists |
-
2021
- 2021-12-20 US US17/556,188 patent/US20220257580A1/en not_active Abandoned
- 2021-12-20 JP JP2023536958A patent/JP2024500752A/ja active Pending
- 2021-12-20 CA CA3205474A patent/CA3205474A1/en active Pending
- 2021-12-20 MX MX2023007420A patent/MX2023007420A/es unknown
- 2021-12-20 IL IL303776A patent/IL303776A/en unknown
- 2021-12-20 CN CN202180087297.8A patent/CN116635075A/zh active Pending
- 2021-12-20 KR KR1020237024556A patent/KR20230124981A/ko unknown
- 2021-12-20 WO PCT/US2021/064350 patent/WO2022140258A1/en active Application Filing
- 2021-12-20 AU AU2021410668A patent/AU2021410668A1/en active Pending
- 2021-12-20 EP EP21911973.2A patent/EP4262800A1/en active Pending
- 2021-12-21 TW TW110148006A patent/TW202241423A/zh unknown
-
2023
- 2023-06-20 CL CL2023001836A patent/CL2023001836A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202241423A (zh) | 2022-11-01 |
| US20220257580A1 (en) | 2022-08-18 |
| EP4262800A1 (en) | 2023-10-25 |
| CA3205474A1 (en) | 2022-06-30 |
| AU2021410668A9 (en) | 2024-08-01 |
| CN116635075A (zh) | 2023-08-22 |
| WO2022140258A1 (en) | 2022-06-30 |
| MX2023007420A (es) | 2023-06-29 |
| KR20230124981A (ko) | 2023-08-28 |
| JP2024500752A (ja) | 2024-01-10 |
| IL303776A (en) | 2023-08-01 |
| AU2021410668A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001836A1 (es) | Tratamiento de glomerulopatía c3 usando un inhibidor de c5a | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| ZA201804513B (en) | Method of treating c3 glomerulopathy | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| TWD196868S (zh) | 超音波治療手持件 | |
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
| MX2021011110A (es) | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. | |
| MX2021002556A (es) | Tratamiento del dolor postquirurgico. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2022000845A (es) | Compuestos inhibidores. | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| NI201700024A (es) | Tratamientos médicos a base de anamorelina | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| MX2022000545A (es) | Inhibidores de enzimas. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине |